Results of a Pilot Study Involving the Use of an Antisense Oligodeoxynucleotide Directed Against the Insulin-Like Growth Factor Type I Receptor in Malignant Astrocytomas

Preclinical animal experiments support the use of an antisense oligodeoxynucleotide directed against the insulin-like growth factor type I receptor (IGF-IR/AS ODN) as an effective potential antitumor agent. We performed a human pilot safety and feasibility study using an IGF-IR/AS ODN strategy in pa...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of clinical oncology 2001-04, Vol.19 (8), p.2189-2200
Hauptverfasser:	ANDREWS, David W, RESNICOFF, Mariana, FLANDERS, Adam E, KENYON, Lawrence, CURTIS, Mark, MERLI, Gino, BASERGA, Renato, ILIAKIS, George, AIKEN, Robert D
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Antineoplastic agents Apoptosis Astrocytoma - therapy Biological and medical sciences Brain Neoplasms - therapy Chemotherapy Female Genetic Therapy Humans Insulin-Like Growth Factor I - genetics Insulin-Like Growth Factor I - pharmacology Magnetic Resonance Imaging Male Medical sciences Middle Aged Oligodeoxyribonucleotides, Antisense - therapeutic use Pharmacology. Drug treatments Pilot Projects Receptors, Somatomedin - genetics Receptors, Somatomedin - physiology Treatment Outcome Tumor Cells, Cultured Venous Thrombosis - etiology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!